A Phase III, Uncontrolled Trial to Assess the Non-immunogenicity and Safety of Org 36286 in Patients Undergoing Repeated Controlled Ovarian Stimulation Cycles Using a Multiple Dose GnRH Antagonist Protocol.

Trial Profile

A Phase III, Uncontrolled Trial to Assess the Non-immunogenicity and Safety of Org 36286 in Patients Undergoing Repeated Controlled Ovarian Stimulation Cycles Using a Multiple Dose GnRH Antagonist Protocol.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Corifollitropin alfa (Primary) ; Chorionic gonadotropin; Follicle stimulating hormones; Gonadotropin releasing hormone; Progesterone
  • Indications Infertility
  • Focus Adverse reactions; Registrational
  • Acronyms TRUST
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 31 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jun 2008 The expected completion date for this trial is now 1 Jul 2009, as reported by ClinicalTrials.gov.
    • 17 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top